Back

Aberrant DNA repair is a vulnerability in histone H3.3-mutant brain tumors

Rondinelli, B.; Giacomini, G.; Piquet, S.; Chevallier, O.; Dabin, J.; Bai, S.-K.; Kim, B.; Siddaway, R.; Raught, B.; Coyaud, E.; Shan, C.-M.; Reid, R. J. D.; Toda, T.; Rothstein, R.; Wilhelm, T.; Barra, V.; Crane, A.; Dubois, F.; Bandopadhayay, P.; Beroukhim, R.; Naim, V.; Jia, S.; Hawkins, C.; Polo, S. E.

2022-09-30 cancer biology
10.1101/2022.09.29.510093 bioRxiv
Show abstract

Pediatric high-grade gliomas (pHGG) are devastating and incurable brain tumors with recurrent mutations in histone H3.3. These mutations promote oncogenesis by dysregulating gene expression through alterations of histone modifications. We identify aberrant DNA repair as an independent oncogenic mechanism, which fosters genome instability and tumor cell growth in H3.3 mutant pHGG, thus opening new therapeutic options. The two most frequent H3.3 mutations in pHGG, K27M and G34R, drive aberrant repair of replication-associated damage by non-homologous end joining (NHEJ). Aberrant NHEJ is mediated by the DNA repair enzyme Polynucleotide Kinase 3-Phosphatase (PNKP), which shows increased association with mutant H3.3 at damaged replication forks. PNKP sustains the proliferation of cells bearing H3.3 mutations, thus conferring a molecular vulnerability, specific to mutant cells, with potential for therapeutic targeting.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.